Sort
23,748 grants matching “melanoma”
Targeting Tumors with NF1 Loss
$547,736Yolanda Sanchez · Dartmouth College · R01 · FY2016 · NS
Functional and Therapeutic Significance of PLK4 in Melanoma
$547,582Nihal Ahmad · University Of Wisconsin-Madison · R01 · FY2025 · CA
Functional and Therapeutic Significance of PLK4 in Melanoma
$547,582Nihal Ahmad · University Of Wisconsin-Madison · R01 · FY2022 · CA
Multimeric Ligands for Targeting of Melanoma
$547,489University Of Arizona · R01 · FY2004 · CA
Genetic Epidemiology of Melanoma (GenoMel)
$547,325Peter A Kanetsky · H. Lee Moffitt Cancer Ctr & Res Inst · R01 · FY2015 · CA
Discovery of Somatic Noncoding Variants that Serve as Drivers in Pediatric Cancers
$547,191Jinghui Zhang · St. Jude Children'S Research Hospital · R01 · FY2019 · CA
CENTRAL TOLERANCE BLOCKADE TO AUGMENT CHECKPOINT IMMUNOTHERAPY IN MELANOMA
$547,185University Of North Carolina At Chapel Hill · · FY2015 · Department of the Army
The Nodal Signaling Pathway In Embryonic Development
$547,096Michael Kuehn · Division Of Basic Sciences - Nci · ZIA · FY2010 · CA
Targeting the vasculature to enhance anti-tumor immunity
$547,081Andrew Carl Dudley · University Of Virginia · R01 · FY2025 · CA
Modifying Young Adult Skin Cancer Risk and Protective Behaviors (UV4.me2):A Hybrid Type 2 Dissemination/Effectiveness Trial
$547,041Carolyn J. Heckman · Rbhs -Cancer Institute Of New Jersey · R01 · FY2019 · CA
EZH2 in cancer biology and novel inhibitors
$546,990Jun Qi · Dana-Farber Cancer Inst · R01 · FY2018 · CA
Dissecting single cell dynamics that coordinate neural crest migration and diversification
$546,908Thomas F Schilling · University Of California-Irvine · R01 · FY2022 · DE
Identification and characterization of cancer cell states by novel computational and experimental technologies - Resubmission - 1
$546,816Itai Yanai · New York University School Of Medicine · U01 · FY2024 · CA
Disclosing Genomic Incidental Findings in a Cancer Biobank: An ELSI Experiment
$546,546Gloria M. Petersen · Mayo Clinic Rochester · R01 · FY2013 · CA
Activating Native Tumor Immunity with IL-33 Armored CARs
$546,511Yina Hsing Huang · Dartmouth College · R01 · FY2024 · CA
An integrated approach to melanoma metastasis and therapy resistance: effects of age-related changes in the ECM and the biomechanics of the skin
$546,285Ashani T Weeraratna · Johns Hopkins University · R01 · FY2021 · CA
Project 1: Multi-scale modeling of adaptive drug resistance in BRAF-mutant melanoma
$546,237Peter Karl Sorger · Harvard Medical School · U54 · FY2021 · CA
Diversification of Cytotoxic Effector Cells Via LPS-activated DCs
$546,210Anna Karolina Palucka · Baylor Research Institute · R01 · FY2009 · CA
Background free amplified single-molecule FISH for in situ and flow cytometric applications
$546,183Sanjay Tyagi · Rbhs-New Jersey Medical School · R01 · FY2022 · CA
Novel molecular imaging approaches to monitor gene and cell-based therapies
$546,171Caius Gabriel Radu · University Of California Los Angeles · R01 · FY2013 · CA
Targeting Lymph Node Dependent Immune Tolerance in Cancer
$546,149Edgar G. Engleman · Stanford University · R01 · FY2025 · CA
PD-1 blockade with cryoablation and dendritic vaccine to treat lymphoma
$545,997Yi Lin · Mayo Clinic Rochester · R01 · FY2017 · CA
Regulation of the Melanocyte Lineage by the AP2 Transcription Factor Family
$545,922Robert Aaron Cornell · University Of Washington · R01 · FY2022 · AR
Defining the role of NF1 and SPRED1 loss in melanoma
$545,876Iwei Yeh · University Of California, San Francisco · R37 · FY2021 · CA
TARGETING ANGIOGENESIS WITH TOXIN VEGF FUSION PROTEINS
$545,700Sibtech, Inc. · R44 · FY2001 · CA